MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
Váldodahkkit: | , , , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Conference item |
Giella: | English |
Almmustuhtton: |
Elsevier
2022
|